*Nebert Card Version 1.1 M-5G-0000160G-04-2024 This document has been approved by Health Sciences Authority (HSA), Singapore on 05/Mar/2024

[Optional] Date(s) of subsequent Columvi® infusion:

Date of Columvi® initiation:

Prescribing Doctor's name:

Patient's name:

Prescribing Doctor's phone number:

Contact Information



Important Safety Information for Patients receiving Columvi^{*} (glofitamab) Patient Card

- Please carry this card with you at all times while you are receiving Columvi® (glofitamab)
- · Show this card to any doctor involved in your care.

Information for the Patient

Contact your Doctor or get emergency help **right away** if you have **any** of these symptoms:

- Fever (100.4°F/38°C or higher)
- · Fast heartbeat
- · Chills
- · Shortness of breath
- Feeling dizzy or lightheaded

Experiencing any of these symptoms could be due to **Cytokine Release Syndrome**, which requires immediate evaluation by a Doctor.

Cytokine Release Syndrome

- is a group of symptoms caused by small proteins called cytokines, released in your body during inflammation.
- · may be caused by receiving Columvi® (glofitamab)

Information for the Treating Doctor

This patient has received Columvi* (glofitamab) - which may cause Cytokine Release Syndrome (CRS).

- · Evaluate the patient immediately and treat symptoms.
- If CRS is suspected, please refer to section 2.2 of the Columvi° (glofitamab) Singapore Package Insert for further information on CRS management.
- Contact the prescribing doctor when possible they may need to modify the next infusion of Columvi® (glofitamab).
- For more information about Columvi® (glofitamab), please refer to the Singapore Package Insert.
- Company contact point Roche Drug Safety Unit at singapore.drugsafety@roche.com